From the looks of it, pharmacy is the place to be.
The global sector has hundreds of players, private and public, and household brands like Pfizer Inc. (NYSE:
PFE), Merck & Co., Inc. (NYSE: MRK) and Eli Lilly and Co (NYSE: LLY) have long dominated the crowded field.
Even so, and despite the slow and tedious work of developing drugs and securing regulatory approval, new players continue to
emerge. In fact, some are pivoting from their established niches and fundamental focuses to partake in the industry, which is
expected to become a
$1.12 trillion market in 2022.
Samsung Electronics (OTC: SSNLF) rolled out
its pharmaceutical line Monday with a replicate of Johnson & Johnson (NYSE: JNJ)’s rheumatoid arthritis drug, Remicade. The South Korean electronics manufacturer
will distribute the treatment at a 35 percent discount.
Samsung Bioepsis Co. will continue to produce biosimilars
to compete with name-brand drugs.
Meanwhile, Amazon.com, Inc. (NASDAQ: AMZN) is taking
on the role of pharmacy benefit manager, or PBM, and is primarily poised to disrupt the generic drug market.
The firm expanded its empire in May with the hiring of a new general manager charged with recruiting pharmaceutical
experts.
The anticipated competition could also catalyze a lowering of drug pricing.
“We believe its [Amazon’s] eventual rollout could provide further downward pressure on prescription drug pricing, as Amazon’s
entry may lead to increased competition among distributors/pharmacies,” Wells Fargo analyst David Maris said in a June
note.
Related Links:
Your
Guide To 2017's Emerging Pharmaceuticals Catalysts
Pharmaceuticals Abound
Among This Week's 11 IPOs
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.